title: Role of Gut Microbiota in Liver Disease.
abstract: Many lines of research have established a relationship between the gut microbiome and patients with liver disease. For example, patients with cirrhosis have increased bacteremia, increased blood levels of lipopolysaccharide, and increased intestinal permeability. Patients with cirrhosis have bacterial overgrowth in the small intestine. Selective intestinal decontamination with antibiotics is beneficial for patients with decompensated cirrhosis. In experimental models of chronic liver injury with fibrosis, several toll-like receptors (TLR) are required to make mice sensitive to liver fibrosis. The presumed ligand for the TLRs are bacterial products derived from the gut microbiome, and TLR knockout mice are resistant to liver inflammation and fibrosis. We and others have characterized the association between preclinical models of liver disease in mice with the microbial diversity in their gut microbiome. In each model, including intragastric alcohol, bile duct ligation, chronic carbon tetrachloride (CCl4), administration, and genetic obesity, there is a significant change in the gut microbiome from normal control mice. However, there is not a single clear bacterial strain or pattern that distinguish mice with liver injury from controlled mice. So how can the gut microbiota affect liver disease? We can identify at least 6 changes that would result in liver injury, inflammation, and/or fibrosis. These include: (1) changes in caloric yield of diet; (2) regulation of gut permeability to release bacterial products; (3) modulation of choline metabolism; (4) production of endogenous ethanol; (5) regulation of bile acid metabolism; and (6) regulation in lipid metabolism.
authors.affiliation: *Department of Medicine, University of California San Diego, La Jolla, CA †Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine ‡Department of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Korea.
authors.forename: David A
authors.initials: DA
authors.lastname: Brenner
authors.forename: Yong-Han
authors.initials: YH
authors.lastname: Paik
authors.forename: Bernd
authors.initials: B
authors.lastname: Schnabl
mesh_terms: D000818:Animals; D001647:Bile Acids and Salts / Q000378:metabolism; D002794:Choline / Q000378:metabolism; D004032:Diet; D000431:Ethanol / Q000378:metabolism; D000069196:Gastrointestinal Microbiome; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000382:microbiology; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology*; D008024:Ligands; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism / Q000382:microbiology*; D008106:Liver Cirrhosis, Experimental / Q000382:microbiology*; D008107:Liver Diseases / Q000382:microbiology*; D051379:Mice; D010539:Permeability; D051193:Toll-Like Receptors / Q000378:metabolism
chemical_list: D001647:Bile Acids and Salts; D008024:Ligands; D051193:Toll-Like Receptors; D000431:Ethanol; D002794:Choline